Author:
Yamane Brett,Carlisle L. Lee,King Bryan
Publisher
Springer International Publishing
Reference28 articles.
1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65(2), 267–272.
2. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. The American Journal of Psychiatry, 141(10), 1195–1202.
3. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17(4), 640–655.
4. Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 835–843. https://doi.org/10.1097/00004583-199706000-00022.
5. Cohen, I. L., Campbell, M., & Posner, D. (1980). A study of haloperidol in young autistic children: A within-subjects design using objective rating scales. Psychopharmacology Bulletin, 16(3), 63–65.